Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Velcade bortezomib: Phase II; approved for multiple myeloma (MM)

In an ongoing U.S. Phase II trial of Velcade as monotherapy in

Read the full 122 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE